Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. - Wikidata - awgldk - TriplyDB

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

http://www.wikidata.org/entity/Q33688726

about

The fate of chemoresistance in triple negative breast cancer (TNBC)Quantification of HER family receptors in breast cancer Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.Targeted Therapies in Breast Cancer: New Approaches and Old Challenges Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium.Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.The BMP inhibitor DAND5 in serum predicts poor survival in breast cancer Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.Improving accuracy of breast cancer biomarker testing in India.An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.

P2860

Q26775232-1FC6A7C9-1513-4ED3-B6E5-63D79B7832B4 Q27015506-47F35F40-58E0-40E9-8C8F-2CA39BC98A61 Q28554412-981C07F0-26F7-4EF8-BE85-3ED0AEB28C55 Q33736780-38558386-AF11-4E72-9A61-9F4553BE1C6C Q33769821-197C1ACE-B5F3-47CE-8E54-361525E6972A Q35845600-9013B394-566C-4AE9-83FC-2DA25CF6AF94 Q36058363-CC5C02EA-F443-4BAF-9A89-D31BCD3249DE Q36064908-1A586004-CB88-433F-BDF5-A436C6044534 Q36070547-AD44B3A8-26C8-48D9-9B61-3DA983B7126C Q36655887-59C9FAE1-6BFF-4482-B7E0-3B1AD78B892E Q36757904-E371F2B3-60B7-4CF5-8289-71E7B5A8E0EF Q36907273-7D71A055-C37C-44DF-AA19-1E0217B2530A Q37045365-74FDAE82-C2DE-42C5-B8EC-FD7684B1EC56 Q37046761-4B4EE9EE-4E54-4518-9DD4-D3D9B51650A9 Q38430990-413EAC8C-E9C2-489E-A9E0-6FA1E288B00C Q39106157-A5C9BAE7-7C72-454A-AE01-9F01B95B9986 Q42316809-109EFD2B-D1D5-4A32-98CC-52AFC275BED6 Q47260496-131596EF-8ADE-408F-93C7-FEB59CCFA9A8 Q50056206-76661F40-790D-48D8-8574-F575505325EC Q51663878-C3174E56-2EAF-4764-B14A-9AE9DDBBDCED

P2860

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

http://www.wikidata.org/entity/Q33688726

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Central pathology laboratory r ...... N063D (Alliance)] ring study.

@ast

Central pathology laboratory r ...... N063D (Alliance)] ring study.

@en

type

label

Central pathology laboratory r ...... N063D (Alliance)] ring study.

@ast

Central pathology laboratory r ...... N063D (Alliance)] ring study.

@en

prefLabel

Central pathology laboratory r ...... N063D (Alliance)] ring study.

@ast

Central pathology laboratory r ...... N063D (Alliance)] ring study.

@en

P1433

Q33688726-1CC47130-64CA-43A9-9F75-671BB6CA3C31

P1476

Q33688726-637C40A2-6DC4-46C0-A109-8C61CBD097B9

P2093

Q33688726-288EBFB0-9F1B-43FE-A0B3-7606A1011C8C

Q33688726-318B3A2E-60F6-4583-850E-06DA1FA71D5B

Q33688726-471254EE-722F-40C3-ADC6-98F1C1D6E5E1

Q33688726-63308850-A7F9-4FF4-9188-B1F37306DEBC

Q33688726-67E37705-3203-490E-B8B1-D3006A38304C

Q33688726-6C2F99D5-11E1-4294-85C6-75F9B5DCAA2D

Q33688726-6D8E865A-F670-4FF3-AF4C-EC43B429B722

Q33688726-8C4FAB92-6B08-4DEB-A67E-D2089F789E00

Q33688726-A90FCF78-15E4-4F1B-A27D-D30436673486

Q33688726-CA4EF88C-47CB-4906-97E0-47EE3A638F98

P2860

Q33688726-5D3CF3DC-FA72-4B76-88F5-72BE72141735

Q33688726-64BFBCEB-F3F3-4F34-80F0-FB56E3BFFACC

Q33688726-67DCCDB8-CACE-40E2-8D93-C2558B690E7F

Q33688726-70731A34-36EC-4028-A653-903B85647ED7

Q33688726-73F20971-E2D7-478C-9E2B-3EA6B17B4B64

Q33688726-75494892-1C98-4CB1-84CC-C2B9DC1520FB

Q33688726-76DE8194-053A-4119-8896-194AB88957B3

Q33688726-F2F5D74D-549E-4952-955A-3A707B6F25BB

P2888

Q33688726-04575133-FB1E-4074-98B6-9AFB97C1EC19

P304

Q33688726-41C18F8F-EF75-4F0A-8338-42A93277B3B4

P31

Q33688726-AFF61B0F-7287-4822-82CD-E033616A7AC0

P356

Q33688726-23FFD941-ED46-4B38-8F25-C73C0910CDA4

P407

Q33688726-F2468482-20DB-46E7-A72F-A95409AA2505

P433

Q33688726-CEBF0038-CA0B-4882-860F-D7E7A02BB1C6

P478

Q33688726-D9CBC1F0-4A7D-40FF-AEF1-E71BA2818723

P50

Q33688726-5FD15D3C-9A62-475E-A3A8-D943CF86CBF0

Q33688726-C7EC039A-5D11-4A21-9063-752EFB76B4D9

Q33688726-F3B459B1-0A5C-4312-90CC-F5EE18D6D0FF

P577

Q33688726-3D332236-A6FE-470C-B3E2-245FDF330628

P5875

Q33688726-E87E29D6-557D-4CBC-A0A5-36CA914F36E9

P6179

Q33688726-BACF3889-9DAE-4594-BC7A-A007C1D544AE

P698

Q33688726-5E38CA6A-5989-46F5-BF36-8A88C6551906

P921

Q33688726-7e3b4550-58ae-4aa8-9e9d-72df9a8420fb

P932

Q33688726-6A597D91-223E-4779-93C2-FF9ADD443B31

P356

S10549-013-2827-0

P1433

Breast Cancer Research and Treatment

P1476

Central pathology laboratory r ...... N063D (Alliance)] ring study.

@en

P2093

Amylou C Dueck

http://www.w3.org/2001/XMLSchema#string

Ann E McCullough

http://www.w3.org/2001/XMLSchema#string

Beiyun Chen

http://www.w3.org/2001/XMLSchema#string

Christian Jackisch

http://www.w3.org/2001/XMLSchema#string

Edith A Perez

http://www.w3.org/2001/XMLSchema#string

Leila Russo

http://www.w3.org/2001/XMLSchema#string

Monica M Reinholz

http://www.w3.org/2001/XMLSchema#string

Patrizia Dell'orto

http://www.w3.org/2001/XMLSchema#string

Richard D Gelber

http://www.w3.org/2001/XMLSchema#string

Robert B Jenkins

http://www.w3.org/2001/XMLSchema#string

P2860

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

Standardization of HER2 testing: results of an international proficiency-testing ring study.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

P2888

s10549-013-2827-0

P304

485-492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-013-2827-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

143

http://www.w3.org/2001/XMLSchema#string

P50

Martine Piccart-Gebhart

P577

2014-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259607578

http://www.w3.org/2001/XMLSchema#string

P6179

1035490900

http://www.w3.org/2001/XMLSchema#string

P698

24395109

http://www.w3.org/2001/XMLSchema#string

P921

P932

4039190

http://www.w3.org/2001/XMLSchema#string